Review article

Hormonal resistance in breast- and prostate cancer

BORISLAV BELEV ; Clinical Hospital Center Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia
DAMIR VRBANEC ; Clinical Hospital Center Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia

Abstract

Breast and prostate cancers are the most common malignant disease in female and male world population, respectively. Both of these tumors are predominantly hormonal-dependent, what is rationale for the widely used endocrine treatment, with specific approach in each of them. Although endocrine treatment is obviously effective and responsible for prolonged progression-free survival and even survival, the problem is that breast and prostate cancers inevitably become "hormone-resistant". The paradigm of treatment has to be changed and today there are some ways to overcome these lack of endocrine responsivness. It is known better today whichmechanisms
are involved in hormone-resistance, and they are numerous, so the designation of new drugs with key features necessary activity in hormone-resistant tumors. In breast cancer, there are selective estrogen modulators as a way to overcome this problem; there is also a combination of receptor-tyrosine kinase and hormonal treatment documented as active in such cases. On the other hand, abirateron-acetat and enzalutamide as a new androgen-receptor-signalling inhibitors proved that androgen signalling cascade is
still active even in a castration-resistant prostate cancer.

Keywords

Hrčak ID:

101259

URI

https://hrcak.srce.hr/101259

Publication date:

30.9.2012.

Visits: 1.702 *